Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Frelaut

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
The Oncologist|April 7, 2023
External Validity of Two Scores for Predicting the Risk of Chemotherapy Toxicity Among Older Patients With Solid Tumors: Results From the ELCAPA Prospective CohortMaxime Frelaut, Elena Paillaud, Guillaume Beinse, et al.
The Journal of Nutrition, Health & Aging|March 22, 2024
Prognostic impact of neurocognitive disorders in older patients with cancer: the ELCAPA prospective cohort studyCatherine Conti, Elena Paillaud, Marie Laurent, et al.
JAMA Network Open|September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung CancerAdrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
Cancer Medicine|November 8, 2023
Cancer mortality and competing causes of death in older adults with cancer: A prospective, multicentre cohort study (ELCAPA-19)Déborah Assouan, Elena Paillaud, Philippe Caillet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 1, 2026
Non-Small Cell Lung Cancer (NSCLC) in Vulnerable and Special Populations: Towards Personalized CareClaudia Parisi, Andrea De Giglio, Marco Banini, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2023
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancerAdrien Rousseau, Marco Tagliamento, Edouard Auclin, et al.
Nutrients|March 11, 2023
Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer TreatmentAnne-Laure Couderc, Evelyne Liuu, Pascaline Boudou-Rouquette, et al.
Journal of Geriatric Oncology|May 21, 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 studySébastien Gendarme, Sonia Zebachi, Romain Corre, et al.
JAMA Oncology|April 9, 2026
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received PembrolizumabAdrien Rousseau, Stéphanie Foulon, David Planchard, et al.
JCO Precision Oncology|January 7, 2022
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Grégoire Marret, Ivan Bièche, Célia Dupain, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
The Oncologist|April 7, 2023
External Validity of Two Scores for Predicting the Risk of Chemotherapy Toxicity Among Older Patients With Solid Tumors: Results From the ELCAPA Prospective CohortMaxime Frelaut, Elena Paillaud, Guillaume Beinse, et al.
The Journal of Nutrition, Health & Aging|March 22, 2024
Prognostic impact of neurocognitive disorders in older patients with cancer: the ELCAPA prospective cohort studyCatherine Conti, Elena Paillaud, Marie Laurent, et al.
JAMA Network Open|September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung CancerAdrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
Cancer Medicine|November 8, 2023
Cancer mortality and competing causes of death in older adults with cancer: A prospective, multicentre cohort study (ELCAPA-19)Déborah Assouan, Elena Paillaud, Philippe Caillet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 1, 2026
Non-Small Cell Lung Cancer (NSCLC) in Vulnerable and Special Populations: Towards Personalized CareClaudia Parisi, Andrea De Giglio, Marco Banini, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2023
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancerAdrien Rousseau, Marco Tagliamento, Edouard Auclin, et al.
Nutrients|March 11, 2023
Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer TreatmentAnne-Laure Couderc, Evelyne Liuu, Pascaline Boudou-Rouquette, et al.
Journal of Geriatric Oncology|May 21, 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 studySébastien Gendarme, Sonia Zebachi, Romain Corre, et al.
JAMA Oncology|April 9, 2026
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received PembrolizumabAdrien Rousseau, Stéphanie Foulon, David Planchard, et al.
JCO Precision Oncology|January 7, 2022
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Grégoire Marret, Ivan Bièche, Célia Dupain, et al.
Pageof 3